Company Overview - ResMed Inc. (RMD) is a San Diego-based company that manufactures, distributes, and markets medical devices and cloud-based software applications, with a market cap of $36 billion [1] - The company specializes in products for respiratory disorders, including diagnostic tools, cloud-based patient monitoring platforms, and out-of-hospital software solutions [1] Market Position - RMD is classified as a large-cap stock, reflecting its significant size and influence in the medical instruments & supplies industry [2] - The company's competitive advantage lies in its diversified portfolio in sleep and respiratory care, strong brand recognition, and technological innovations such as AI-powered therapy and remote monitoring [2] - ResMed operates in over 140 countries, leveraging its global presence to maintain its market leadership [2] Stock Performance - RMD's stock has experienced an 18.3% decline from its 52-week high of $293.81, reached on August 22, 2025 [3] - Over the past three months, RMD stock has decreased by 4.9%, underperforming the Nasdaq Composite's 3.7% losses during the same period [3] - Year-to-date, RMD shares have fallen slightly, outperforming the Nasdaq's YTD losses of 2.3%, but the stock has only increased by 6.4% over the past 52 weeks, significantly lagging behind the Nasdaq's 30.3% returns [3] Technical Analysis - RMD has been trading below its 200-day moving average since late October 2025, indicating a bearish trend, and is also trading below its 50-day moving average recently [4] Financial Performance - In its Q2 results, RMD reported an adjusted EPS of $2.81, exceeding Wall Street's expectations of $2.69, and revenue of $1.42 billion, surpassing forecasts of $1.39 billion [5] - In comparison, Baxter International Inc. (BAX) has underperformed RMD, with a 5.6% decline year-to-date and a 49.7% drop over the past 52 weeks [5]